Page 17 - 《中国药科大学学报》2025年第4期

第 56 卷第 4 期 贾佳庆，等：核酸模式识别机制及其化学干预的研究进展 413

干预。值得注意的是，多数模式识别受体通路既能 [7] Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-like recep-
够作为肿瘤抑制因子调控肿瘤免疫微环境，诱导持 tors (TLRs), NOD-like receptors (NLRs), and RIG-I-like recep-
tors (RLRs) in innate immunity. TLRs, NLRs, and RLRs lig-
久的抗肿瘤免疫作用；也能够促进肿瘤的生长和转 ands as immunotherapeutic agents for hematopoietic
移，其慢性激活可以矛盾地诱导免疫抑制性肿瘤微 diseases[J]. Int J Mol Sci, 2021, 22(24): 13397.
环境。因此，既需平衡受体过度活化与免疫耐受的 [8] Krall JB, Nichols PJ, Henen MA, et al. Structure and formation
of Z-DNA and Z-RNA[J]. Molecules, 2023, 28(2): 843.
调控，又需克服靶向特异性不足、信号网络复杂性 [9] Lind NA, Rael VE, Pestal K, et al. Regulation of the nucleic
及递送系统瓶颈等关键问题——这构成了相关药 acid-sensing toll-like receptors[J]. Nat Rev Immunol, 2022,
物开发的核心科学挑战，亦是抗炎抗肿瘤药物临床 22(4): 224-235.
[10] Sheng CJ, Zeng Q, Yao C, et al. Advances in the innate im-
转化的根本障碍。 mune recognition of nucleic acids[J]. Chin J Cell Biol, 2025,
未来核酸免疫药物研究还需加强与前沿技术 47(3): 403-411.
的深度融合。在药物发现阶段，利用机器学习等人 [11] van Eijck CWF, Haddaoui HE, Kucukcelebi S, et al. Rinta-
tolimod in advanced pancreatic cancer enhances antitumor im-
工智能辅助，提高虚拟筛选的速度与准确度，加速 munity through dendritic cell-mediated T-cell responses[J]. Clin
靶向 PRRs 药物的发现；通过整合合成生物学、点 Cancer Res, 2024, 30(16): 3447-3458.
击化学等新兴技术实现研究创新，协同变构调控及 [12] Klute K, Picozzi VJ, Gabrail N, et al. Phase 2 randomized study
of rintatolimod following FOLFIRINOX in patients with local-
泛素化降解等机制干预策略，构建多通路协同靶向 ly advanced pancreatic adenocarcinoma[J]. J Clin Oncol, 2024,
体系。重点探索 PRRs 间的时空精准调控方案，以 42(16_suppl): TPS4214.
平衡抗病毒效力与免疫稳态，研究出兼具高选择 [13] De Waele J, Verhezen T, van der Heijden S, et al. A systematic
review on poly(I: C) and poly-ICLC in glioblastoma: adjuvants
性、低毒性及良好成药性的核酸免疫药物。该领域 coordinating the unlocking of immunotherapy[J]. J Exp Clin
发展亟需多学科深度协作：一方面深度挖掘创新靶 Cancer Res, 2021, 40(1): 213.
点并开发智能响应型递送载体，另一方面聚焦核酸 [14] Hu ZT, Leet DE, Allesøe RL, et al. Personal neoantigen vac-
cines induce persistent memory T cell responses and epitope
免疫识别中的机制盲区，驱动原创药物设计。值得 spreading in patients with melanoma[J]. Nat Med, 2021, 27(3):
注意的是，老药新用与联合疗法已成为临床转化新 515-525.
趋势。通过精准靶向递送、优化联合用药方案、鉴 [15] Alvarez M, Molina C, Garasa S, et al. Intratumoral neoadjuvant
immunotherapy based on the BO-112 viral RNA mimetic[J].
定预测性生物标志物及深化机制研究，结合多模态
Oncoimmunology, 2023, 12(1): 2197370.
技术协同策略，靶向 PRRs 的下一代免疫调节剂有 [16] Malcolm BA, Aerts CA, Dubois KJ, et al. PrEP-001 prophylac-
望突破现有免疫疗法响应率瓶颈，为临床转化开辟 tic effect against rhinovirus and influenza virus - RESULTS of
2 randomized trials[J]. Antiviral Res, 2018, 153: 70-77.
新路径。
[17] Qu SH, Qin TJ, Li M, et al. The effects of resiquimod in an
ovalbumin-induced allergic rhinitis model[J]. Int Immunophar-
macol, 2018, 59: 233-242.
References
[18] Sharma M, Carvajal RD, Hanna GJ, et al. Preliminary results
[1] Sompayrac L. How the Immune System Works[M]. 6th ed. from a phase 1/2 study of BDC-1001, a novel HER2 targeting
New York: Wiley, 2019: 13-26. TLR7/8 immune-stimulating antibody conjugate (ISAC), in pa-
[2] Land WG. Prologue: about DAMPs, PAMPs, and MAMPs[M]// tients (pts) with advanced HER2-expressing solid tumors[J]. J
Damage-Associated Molecular Patterns in Human Diseases: Clin Oncol, 2021, 39(15_suppl): 2549.
Volume 1: Injury-Induced Innate Immune Responses. Cham: [19] Diab A, Curti B, Bilen M, et al. 368 REVEAL: phase 1 dose-es-
Springer International Publishing, 2018: 191-217. calation study of NKTR-262, a novel TLR7/8 agonist, plus be-
[3] Liu SD, Xu PL. Advancements in tyrosine kinase-mediated reg- mpegaldesleukin: local innate immune activation and systemic
ulation of innate nucleic acid sensing[J]. J Zhejiang Univ Med adaptive immune expansion for treating solid tumors[C]//Regu-
Sci (浙江大学学报 医学版), 2024, 53(1): 35-46. lar and Young Investigator Award Abstracts. BMJ Publishing
[4] Fischer S. Pattern recognition receptors and control of innate Group Ltd, 2020: A224.2-A225.
immunity: role of nucleic acids[J]. Curr Pharm Biotechnol, [20] Ke PY. Crosstalk between autophagy and RLR signaling[J].
2018, 19(15): 1203-1209. Cells, 2023, 12(6): 956.
[5] Mercer J, Lee JE, Saphire EO, et al. SnapShot: enveloped virus [21] Jia JL, Fu JG, Tang HM. Activation and evasion of RLR signal-
entry[J]. Cell, 2020, 182(3): 786-786. e1. ing by DNA virus infection[J]. Front Microbiol, 2021, 12:
[6] Junt T, Barchet W. Translating nucleic acid-sensing pathways 804511.
into therapies[J]. Nat Rev Immunol, 2015, 15(9): 529-544. [22] Solstad A, Hogaboam O, Forero A, et al. RIG-I-like receptor